Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088894 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase 3 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
- 1
- Study location
NCT00088894: Completed Phase 3 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
NCT00088894 is a Phase 3 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 590 participants, above the 40-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (1375% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088894, a Phase 3 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase III trial is studying gemcitabine and bevacizumab to see how well they work compared to gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Combining gemcitabine with bevacizumab may kill more tumor cells. It is not yet known whether gemcitabine is more effective with or without bevacizumab in treating pancreatic cancer.
Primary Outcome
Based on the stratified logrank test.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- OTHER pharmacogenomic studies
- BIOLOGICAL bevacizumab
- DRUG gemcitabine hydrochloride
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2004-06 |
| Phase | Phase 3 |
What the finished NCT00088894 record still lists
NCT00088894 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, above the 40-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (1375% higher).
The record links to 5 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00088894 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00088894 about?
NCT00088894 is a clinical study titled "Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". This randomized phase III trial is studying gemcitabine and bevacizumab to see how well they work compared to gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from...
What is the current status of trial NCT00088894?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2004-06.
What conditions does trial NCT00088894 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer.
What interventions are being tested in trial NCT00088894?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), pharmacogenomic studies (OTHER), bevacizumab (BIOLOGICAL), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00088894?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00088894 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00088894's enrollment target sits among peer trials
590 1st of 15 higher than 15 of 15 other Stage IV Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia